The Future of Health Technology Assessment in Pharma

Report Code: PHM233A

|

May 2020

Download a free copy of The Future of Health Technology Assessment in Pharma: A BCC White Paper

  • Cutting-edge knowledge from the Institute for Clinical and Economic Review (ICER), one of the major organizations conducting HTAs.
  • Insight into how coronavirus is impacting the HTA process, including pricing considerations for the experimental COVID19 drug Remdesivir.
  • Breakdown of metrics used to evaluate pharmaceutical drugs.

Complete our form and we'll send you a free copy.